Evotec stock advances as investors weigh 2025 revenue and EBITDA trends

Evotec stock is anchored by the companys 2025 results, which showed revenue of EUR 796.1 million, adjusted EBITDA of EUR 22.6 million, and a net loss of EUR 163.1 million for the year. The figures come from Evotecs investor relations materials at Evotec investor relations.

Revenue above EUR 796 million

The 2025 top line of EUR 796.1 million gives investors a dated reference point for the business, even without a fresh trading update in the available material. That compares with the companys own 2025 operating profit metric, adjusted EBITDA of EUR 22.6 million, which leaves a margin of roughly 2.8% on the reported revenue base.

Loss of EUR 163.1 million

The reported net loss of EUR 163.1 million in 2025 remains the clearest contrast to the revenue base. The gap between sales and bottom-line profitability is the key number for valuation work, because it shows how far the group still sits from sustained earnings conversion.

Evotec also reported a workforce and portfolio profile that still matters for the next reporting cycle, with the company continuing to position itself around drug discovery and development partnerships. For investors, the combination of EUR 796.1 million in revenue, EUR 22.6 million in adjusted EBITDA, and EUR 163.1 million in net loss defines the scale of the turnaround task.

2025 metrics in context

The 2025 figures are the most useful current reference because they are concrete, periodized, and directly comparable inside the companys own reporting set. They also give a quantified comparison inside the same year: adjusted EBITDA was positive at EUR 22.6 million, while the net result was negative by EUR 163.1 million.

That spread matters because it shows the difference between operating leverage at the earnings-before-interest, taxes, depreciation and amortization level and the burden that still sits below it. The market usually reads that split as a test of execution rather than a pure story about revenue growth.

Partnership model matters

Evotecs business model still relies on a mix of discovery collaboration, platform work, and longer-dated pharmaceutical partnerships. In practice, the product angle is less a single consumer item than the companys research engine and partnered pipeline, which is why revenue and EBITDA are the most relevant numbers in the latest available report.

That makes the investor focus unusually binary: either the partnership base and cost discipline narrow the loss, or the 2025 net loss of EUR 163.1 million continues to dominate the equity story. The next visible checkpoint is the companys next reported period through investor relations.

Stock and market level

Evotecs share price is not included here because no dated market quote was available in the provided search results. The article therefore uses the latest evidenced company metrics instead, all drawn from the 2025 reporting year.